Patents by Inventor Bryan D. Smith

Bryan D. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250206729
    Abstract: Described herein are compounds that are dual RAF and tubulin inhibitors and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: December 18, 2024
    Publication date: June 26, 2025
    Inventors: Yu Mi Ahn, Daniel L. Flynn, Bertrand Le Bourdonnec, Bryan D. Smith, Stacie Bulfer, Jeffery Zwicker, Salim Javed, Chase Crawley
  • METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS
    Publication number: 20250205237
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Application
    Filed: March 14, 2025
    Publication date: June 26, 2025
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • Methods of treating disorders using CSF1R inhibitors
    Patent number: 12285430
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: April 29, 2025
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • COMBINATION THERAPY FOR THE TREATMENT OF MASTOCYTOSIS
    Publication number: 20250090506
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
    Type: Application
    Filed: August 26, 2024
    Publication date: March 20, 2025
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
    Publication number: 20240415818
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.
    Type: Application
    Filed: April 10, 2024
    Publication date: December 19, 2024
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • Combination therapy for the treatment of mastocytosis
    Patent number: 12102620
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: October 1, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • METHODS OF TREATING DISORDERS WITH ULK INHIBITORS
    Publication number: 20240180923
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Application
    Filed: August 29, 2023
    Publication date: June 6, 2024
    Inventors: Rodrigo Ruiz Soto, Frederic J. Reu, Matthew L. Sherman, Daniel L. Flynn, Madhumita Bogdan, Bryan D. Smith, Gada Al-Ani
  • Combination therapy for the treatment of gastrointestinal stromal tumor
    Patent number: 11986463
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 21, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS
    Publication number: 20230414614
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Application
    Filed: April 28, 2023
    Publication date: December 28, 2023
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • METHODS FOR TREATING VASCULAR MALFORMATIONS
    Publication number: 20230277522
    Abstract: The present disclosure relates to methods for inhibiting TIE2 kinase useful in the treatment of growth of venous malformations.
    Type: Application
    Filed: August 12, 2020
    Publication date: September 7, 2023
    Inventors: Daniel L. Flynn, Bryan D. Smith, Miikka Vikkula
  • Methods of treating disorders using CSF1R inhibitors
    Patent number: 11679110
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: June 20, 2023
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA
    Publication number: 20220370423
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 24, 2022
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Oliver Rosen, Bryan D. Smith
  • USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA
    Publication number: 20220370424
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1, 6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 24, 2022
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Oliver Rosen, Bryan D. Smith
  • METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS
    Publication number: 20220143018
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Application
    Filed: June 25, 2021
    Publication date: May 12, 2022
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • METHODS FOR TREATING VASCULAR MALFORMATIONS
    Publication number: 20220047573
    Abstract: The present disclosure relates to methods for inhibiting TIE2 kinase useful in the treatment of growth of venous malformations.
    Type: Application
    Filed: August 12, 2020
    Publication date: February 17, 2022
    Inventors: Daniel L. Flynn, Bryan D. Smith, Miikka Vikkula
  • USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA
    Publication number: 20220031678
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.
    Type: Application
    Filed: October 21, 2021
    Publication date: February 3, 2022
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Oliver Rosen, Bryan D. Smith
  • Methods of treating disorders using CSF1R inhibitors
    Patent number: 11103507
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 31, 2021
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
    Publication number: 20210145805
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.
    Type: Application
    Filed: July 30, 2020
    Publication date: May 20, 2021
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA
    Publication number: 20210015801
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea in the treatment of cancers. Specifically, the disclosure is directed to methods of inhibiting PDGFR kinases and treating cancers and disorders associated with inhibition of PDGFR kinases including lung adenocarcinoma, squamous cell lung cancer, glioblastoma, pediatric glioma, astrocytomas, sarcomas, gastrointestinal stromal tumors, malignant peripheral nerve sheath sarcoma, intimal sarcomas, hypereosinophilic syndrome, idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, eosinophilia-associated acute myeloid leukemia, or lymphoblastic T-cell lymphoma.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 21, 2021
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Oliver Rosen, Bryan D. Smith
  • COMBINATION THERAPY FOR THE TREATMENT OF MASTOCYTOSIS
    Publication number: 20200352920
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
    Type: Application
    Filed: July 30, 2020
    Publication date: November 12, 2020
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta